Clinical Trial Update: Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

View source ↗

Summary

A secondary biomarker analysis report on neutrophil-to-lymphocyte ratio in bladder cancer using data from the SWOG 8710 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Bladder Cancer | Status: COMPLETED | Results posted: 2017-03-01